Praluent and Vitamin d3 drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Praluent (alirocumab) and Vitamin d3 (cholecalciferol). Common drug interactions include trismus among females and injection site haemorrhage among males.

The phase IV clinical study analyzes what interactions people have when they take Praluent and Vitamin d3. It is created by eHealthMe based on reports of 50 people who take the same drugs from the FDA, and is updated regularly.

What is Praluent?

Praluent has active ingredients of alirocumab. It is often used in high blood cholesterol. eHealthMe is studying from 24,963 Praluent users. Check the latest studies of Praluent.

What is Vitamin d3?

Vitamin d3 has active ingredients of cholecalciferol. It is often used in heart health. eHealthMe is studying from 32,172 Vitamin d3 users. Check the latest studies of Vitamin d3.

On Aug, 11, 2026

50 people who take Praluent and Vitamin d3 together, and have interactions are studied.

Praluent and Vitamin d3 drug interactions.

What are the common drug interactions of Praluent and Vitamin D3, by gender? *:

female:

Trismus (reduced opening of the jaws)
Abdominal pain
Anaphylactic reaction (serious allergic reaction)
Balance disorder
Blood pressure increased
Blood sodium decreased
Bone pain
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cataract (clouding of the lens inside the eye)
Confusional state

male:

Injection site haemorrhage (bleeding from injection site)
Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
Sinus disorder (disease of sinus)
Visual impairment
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
Arterial occlusive disease (slow process through which arteries throughout the body become progressively narrowed and eventually completely blocked)
Arthralgia (joint pain)
Blood creatinine increased
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Communication disorder (speech and language disorder)

What are the common drug interactions of Praluent and Vitamin D3, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Panic attack
Salivary hypersecretion (excess saliva secretion)
Stent placement
Therapeutic response unexpected
Vomiting

50-59:

Muscle spasms (muscle contraction)
Injection site reaction
Headache (pain in head)
Hypotension (abnormally low blood pressure)
Insomnia (sleeplessness)
Malaise (a feeling of general discomfort or uneasiness)
Spinal pain (pain in spine)
Syncope (loss of consciousness with an inability to maintain postural tone)
Tooth extraction

60+:

Injection site haemorrhage (bleeding from injection site)
Pain
Influenza
Lymphocyte count decreased
Mean cell volume increased (more than normal average red blood cell volume)
Nodule (a growth of abnormal tissue)
Protein total decreased
Psoriasis (immune-mediated disease that affects the skin)
Red blood cell count decreased
Rhinorrhoea (watery mucus discharge from the nose)

What are the existing conditions these people have? *

Hyperlipidaemia (presence of excess lipids in the blood): 13 people, 26.00%
Pain: 4 people, 8.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 8.00%
High Blood Pressure: 3 people, 6.00%

* Approximation only. Some reports may have incomplete information.

Do you take Praluent and Vitamin d3?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously